Reset filter
Palabras clave
B-cellymfoom ×
Mostrar más Palabras clave
Tabla de contenido
  1. 1. Ensayo clínico
    1. 1.1. Determinación de Elegibilidad
    1. 1.2. Historial médico
    1. 1.3. Examen físico
    1. 1.4. Puntuación de evaluación
    1. 1.5. Diagnóstico aparente
    1. 1.6. Laboratorio
    1. 1.7. Patología / Histología
    1. 1.8. Consentimiento
    1. 1.9. Terapia
    1. 1.10. Informe Operativo
    1. 1.11. Acontecimiento adverso
    1. 1.12. Seguimiento
  2. 2. Documentación de rutina
  3. 3. Estudio de registro / cohorte
  4. 4. Seguro de calidad
  5. 5. Estándar de datos
  6. 6. Resultado reportado por el paciente
  7. 7. Especialidad médica
Modelos de datos seleccionados

Debe iniciar sesión para seleccionar modelos de datos para descargar o realizar un análisis.

104 Resultados de la búsqueda.
Relevancia Evaluación Nuevo primero Antiguo primero

Eligibility Mature B-Cell Lymphoma NCT01046825

- 27/9/21 - 1 formulario, 2 itemgroups, 25 items, 1 idioma
Itemgroups: Inclusion Criteria, Exclusion Criteria
Mature B-Cell Lymphoma And Leukemia Study III; ODM derived from: https://clinicaltrials.gov/show/NCT01046825

Screening Demographics GOAL Trial B-cell Lymphoma NCT02499003

- 20/9/21 - 1 formulario, 1 itemgroup, 6 items, 1 idioma
Itemgroup: Demographics
NCT02499003 The GOAL Trial: Rescue Treatment With the Monoclonal Anti CD20-antibody Obinutuzumab (GA101) in Combination With Pixantrone for the Treatment of Patients With Relapsed Aggressive B-cell Lymphoma Study part: Demographics (Screening) Source: Prof. Dr. med. Georg Heß Universitätsmedizin Mainz

Screening Biopsy GOAL Trial B-cell Lymphoma NCT02499003

- 20/9/21 - 1 formulario, 3 itemgroups, 22 items, 1 idioma
Itemgroups: Admininstrative data, Bone marrow biopsy, Biopsy Tumor
NCT02499003 The GOAL Trial: Rescue Treatment With the Monoclonal Anti CD20-antibody Obinutuzumab (GA101) in Combination With Pixantrone for the Treatment of Patients With Relapsed Aggressive B-cell Lymphoma Source: Prof. Dr. med. Georg Heß Universitätsmedizin Mainz

Screening Serology GOAL Trial B-cell Lymphoma NCT02499003

- 20/9/21 - 1 formulario, 1 itemgroup, 8 items, 1 idioma
Itemgroup: Serology Viral
NCT02499003 The GOAL Trial: Rescue Treatment With the Monoclonal Anti CD20-antibody Obinutuzumab (GA101) in Combination With Pixantrone for the Treatment of Patients With Relapsed Aggressive B-cell Lymphoma Visit: Screening. Source: Prof. Dr. med. Georg Heß Universitätsmedizin Mainz

Biopsy GOAL Trial B-cell Lymphoma NCT02499003

- 20/9/21 - 1 formulario, 1 itemgroup, 13 items, 1 idioma
Itemgroup: Biopsy
NCT02499003 The GOAL Trial: Rescue Treatment With the Monoclonal Anti CD20-antibody Obinutuzumab (GA101) in Combination With Pixantrone for the Treatment of Patients With Relapsed Aggressive B-cell Lymphoma. Visit: End of Treatment. Source: Prof. Dr. med. Georg Heß Universitätsmedizin Mainz

Iodine 131 B1 Antibody for B-Cell Lymphomas NCT00950755 - History of Lymphoma

- 20/9/21 - 1 formulario, 5 itemgroups, 21 items, 1 idioma
Itemgroups: Administrative Data, Cell Type, Grade, Extranodal Involvement at Enrollment, CD20 Reactivity
Study ID: 104505 Clinical Study ID: BEX104505 Study Title: Phase II Study of Iodine 131 Anti B1 Antibody for 1st or 2nd Relapsed Indolent B-Cell Lymphomas or B-Cell Lymphomas That Have Transformed to a More Aggressive Histology Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00950755 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: tositumomab Trade Name: Bexxar Study Indication: Lymphoma, Non-Hodgkin

Eligibility Lymphoma, B-Cell NCT00515138

- 20/9/21 - 1 formulario, 2 itemgroups, 21 items, 1 idioma
Itemgroups: Inclusion Criteria, Exclusion Criteria
A Pilot Study of Standard-Dose Rituximab, Ifosfamide, Carboplatin and Etoposide (RICE) Plus Bortezomib (Velcade) in a Dose-Escalating Fashion for Patients With Relapsed or Primary Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma Who Are Candidates for Autologous Stem Cell Transplant; ODM derived from: https://clinicaltrials.gov/show/NCT00515138

Interim-PET and Randomisation PETAL Study NCT00554164 - Interim-PET and Randomisation

- 20/9/21 - 1 formulario, 4 itemgroups, 15 items, 2 idiomas
Itemgroups: Interim-PET und Randomisation, PET, Stratification criteria, Footer module
Positronen-Emissionstomographie-gesteuerte Therapie aggressiver Non-Hodgkin-Lymphome (PETAL-Studie) Universitätsklinikum Essen (UK Essen) EudraCT-Nummer: 2006-001641-33 NCT00554164

NCT01193842 On-Study - AMC-075 Baseline Lymphoma Disease Activity and Assessment Form (LAA) - 3206533v1.0 - AMC-075 Baseline Lymphoma Disease Activity and Assessment Form (LAA)

- 20/9/21 - 1 formulario, 5 itemgroups, 20 items, 1 idioma
Itemgroups: Header Module, Lymphoma Disease Activity and Assessment, Histogenetic subtyping markers, Lymphatic Involvement, Comments
AMC-075 Baseline Lymphoma Disease Activity and Assessment Form (LAA) Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With Previously Untreated HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=9F16C635-12A6-DD97-E040-BB89AD43743A

Eligibility Ocular Adnexal Mucosa-Associated Lymphoid Tissue Lymphoma NCT01514344

- 20/6/21 - 1 formulario, 2 itemgroups, 12 items, 1 idioma
Itemgroups: Inclusion Criteria, Exclusion Criteria
Intralesional Rituximab for the Treatment of Conjunctival Indolent Lymphoma; ODM derived from: https://clinicaltrials.gov/show/NCT01514344

Eligibility Lymphoma, B-Cell, Non-Hodgkin's Lymphoma NCT01724021

- 22/7/20 - 1 formulario, 2 itemgroups, 19 items, 1 idioma
Itemgroups: Inclusion Criteria, Exclusion Criteria
A Study of Patient Preference With Subcutaneous Versus Intravenous MabThera/Rituxan (Rituximab) in Patients With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1, 2 or 3a; ODM derived from: https://clinicaltrials.gov/show/NCT01724021

Eligibility Lymphoma, B-Cell, Lymphoma, Follicular NCT01691898

- 22/7/20 - 1 formulario, 2 itemgroups, 16 items, 1 idioma
Itemgroups: Inclusion Criteria, Exclusion Criteria
A Study of DCDT2980S in Combination With MabThera/Rituxan or DCDS4501A in Combination With MabThera/Rituxan and Evaluation of Combination DCDS4501A and Obinutuzumab in Patients With Non-Hodgkin's Lymphoma; ODM derived from: https://clinicaltrials.gov/show/NCT01691898

Contacto

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Ayuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial